PL1635820T3 - Asenapina do leczenia schizofrenii u pacjenta z nadwagą lub predyspozycją do nadwagi - Google Patents
Asenapina do leczenia schizofrenii u pacjenta z nadwagą lub predyspozycją do nadwagiInfo
- Publication number
- PL1635820T3 PL1635820T3 PL04766041T PL04766041T PL1635820T3 PL 1635820 T3 PL1635820 T3 PL 1635820T3 PL 04766041 T PL04766041 T PL 04766041T PL 04766041 T PL04766041 T PL 04766041T PL 1635820 T3 PL1635820 T3 PL 1635820T3
- Authority
- PL
- Poland
- Prior art keywords
- overweight
- asenapine
- predisposition
- schizophrenia
- patient
- Prior art date
Links
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 title 1
- 229960005245 asenapine Drugs 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03101721 | 2003-06-12 | ||
| PCT/EP2004/051069 WO2004110437A1 (en) | 2003-06-12 | 2004-06-09 | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight |
| EP04766041A EP1635820B1 (en) | 2003-06-12 | 2004-06-09 | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1635820T3 true PL1635820T3 (pl) | 2008-10-31 |
Family
ID=33547705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04766041T PL1635820T3 (pl) | 2003-06-12 | 2004-06-09 | Asenapina do leczenia schizofrenii u pacjenta z nadwagą lub predyspozycją do nadwagi |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20060128688A1 (pl) |
| EP (1) | EP1635820B1 (pl) |
| JP (1) | JP2006527238A (pl) |
| KR (1) | KR20060020664A (pl) |
| CN (1) | CN1816335A (pl) |
| AR (1) | AR044675A1 (pl) |
| AT (1) | ATE395914T1 (pl) |
| AU (1) | AU2004246820B2 (pl) |
| BR (1) | BRPI0411237A (pl) |
| CA (1) | CA2528365A1 (pl) |
| CY (1) | CY1110366T1 (pl) |
| DE (1) | DE602004013966D1 (pl) |
| DK (1) | DK1635820T3 (pl) |
| ES (1) | ES2305829T3 (pl) |
| IL (1) | IL172397A (pl) |
| NO (1) | NO20055884L (pl) |
| NZ (1) | NZ544018A (pl) |
| PL (1) | PL1635820T3 (pl) |
| PT (1) | PT1635820E (pl) |
| RU (1) | RU2352336C2 (pl) |
| SI (1) | SI1635820T1 (pl) |
| TW (1) | TWI327915B (pl) |
| WO (1) | WO2004110437A1 (pl) |
| ZA (1) | ZA200509904B (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1710245T3 (pl) * | 2005-04-07 | 2008-01-31 | Merck Sharp & Dohme | Postać krystaliczna maleinianu asenapiny |
| US7741358B2 (en) | 2005-04-14 | 2010-06-22 | N.V. Organon | Crystal form of asenapine maleate |
| ES3001152T3 (es) | 2016-12-20 | 2025-03-04 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno |
| PL3338768T3 (pl) | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
| WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| EP3810099A1 (en) | 2018-06-20 | 2021-04-28 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine |
| WO2020106330A1 (en) * | 2018-07-18 | 2020-05-28 | Pillsy, Inc. | Smart drug delivery and monitoring device, kit, and method of use for pill compounds |
| US11903945B2 (en) * | 2019-12-11 | 2024-02-20 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
| RU2756614C1 (ru) * | 2021-04-07 | 2021-10-04 | Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) | Способ поддержки принятия врачебных решений выбора антипсихотической терапии у больных шизофренией с целью профилактики акатизии |
| US12616698B2 (en) | 2021-05-05 | 2026-05-05 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1079670C (zh) * | 1994-03-02 | 2002-02-27 | 阿克佐诺贝尔公司 | 舌下或颊给药的药物组合物 |
| US5496831A (en) * | 1994-05-13 | 1996-03-05 | The General Hospital Corporation | Inhibition of insulin-induced adiposis |
| JP2004517112A (ja) * | 2001-01-02 | 2004-06-10 | ファルマシア・アンド・アップジョン・カンパニー | 新規薬物コンビネーション |
-
2004
- 2004-06-03 TW TW093116017A patent/TWI327915B/zh not_active IP Right Cessation
- 2004-06-09 NZ NZ544018A patent/NZ544018A/en not_active IP Right Cessation
- 2004-06-09 US US10/560,554 patent/US20060128688A1/en not_active Abandoned
- 2004-06-09 DK DK04766041T patent/DK1635820T3/da active
- 2004-06-09 BR BRPI0411237-7A patent/BRPI0411237A/pt not_active IP Right Cessation
- 2004-06-09 AU AU2004246820A patent/AU2004246820B2/en not_active Ceased
- 2004-06-09 EP EP04766041A patent/EP1635820B1/en not_active Expired - Lifetime
- 2004-06-09 CN CNA200480018591XA patent/CN1816335A/zh active Pending
- 2004-06-09 PT PT04766041T patent/PT1635820E/pt unknown
- 2004-06-09 WO PCT/EP2004/051069 patent/WO2004110437A1/en not_active Ceased
- 2004-06-09 CA CA002528365A patent/CA2528365A1/en not_active Abandoned
- 2004-06-09 SI SI200430755T patent/SI1635820T1/sl unknown
- 2004-06-09 PL PL04766041T patent/PL1635820T3/pl unknown
- 2004-06-09 AT AT04766041T patent/ATE395914T1/de active
- 2004-06-09 ES ES04766041T patent/ES2305829T3/es not_active Expired - Lifetime
- 2004-06-09 JP JP2006516141A patent/JP2006527238A/ja active Pending
- 2004-06-09 KR KR1020057023646A patent/KR20060020664A/ko not_active Ceased
- 2004-06-09 DE DE602004013966T patent/DE602004013966D1/de not_active Expired - Lifetime
- 2004-06-09 RU RU2006101061/14A patent/RU2352336C2/ru not_active IP Right Cessation
- 2004-06-11 AR ARP040102026A patent/AR044675A1/es unknown
-
2005
- 2005-12-06 IL IL172397A patent/IL172397A/en not_active IP Right Cessation
- 2005-12-06 ZA ZA200509904A patent/ZA200509904B/en unknown
- 2005-12-12 NO NO20055884A patent/NO20055884L/no not_active Application Discontinuation
-
2008
- 2008-06-24 CY CY20081100659T patent/CY1110366T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL172397A (en) | 2010-06-16 |
| WO2004110437A1 (en) | 2004-12-23 |
| JP2006527238A (ja) | 2006-11-30 |
| US20060128688A1 (en) | 2006-06-15 |
| DK1635820T3 (da) | 2008-09-08 |
| EP1635820B1 (en) | 2008-05-21 |
| ZA200509904B (en) | 2006-12-27 |
| NO20055884L (no) | 2006-01-03 |
| CA2528365A1 (en) | 2004-12-23 |
| HK1084894A1 (en) | 2006-08-11 |
| RU2006101061A (ru) | 2006-07-27 |
| CN1816335A (zh) | 2006-08-09 |
| AU2004246820A1 (en) | 2004-12-23 |
| ATE395914T1 (de) | 2008-06-15 |
| IL172397A0 (en) | 2006-04-10 |
| KR20060020664A (ko) | 2006-03-06 |
| SI1635820T1 (sl) | 2008-08-31 |
| ES2305829T3 (es) | 2008-11-01 |
| EP1635820A1 (en) | 2006-03-22 |
| DE602004013966D1 (de) | 2008-07-03 |
| AR044675A1 (es) | 2005-09-21 |
| TWI327915B (en) | 2010-08-01 |
| TW200501946A (en) | 2005-01-16 |
| RU2352336C2 (ru) | 2009-04-20 |
| PT1635820E (pt) | 2008-06-17 |
| AU2004246820B2 (en) | 2009-10-01 |
| CY1110366T1 (el) | 2014-04-09 |
| BRPI0411237A (pt) | 2006-07-11 |
| NZ544018A (en) | 2008-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL173439A0 (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
| AU2003225160A8 (en) | "biosensor for dialysis therapy" | |
| IL219642A0 (en) | Catheter | |
| IL166171A0 (en) | Blood clot-targeted nanoparticles | |
| EP1579833A4 (en) | INDICATOR FOR A BODY FLUID ABSORBABLE ARTICLE | |
| IL172397A0 (en) | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight | |
| GB0314504D0 (en) | Catheter | |
| PL361794A1 (pl) | Cewnik | |
| EP1757282A4 (en) | USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS | |
| ZA200707236B (en) | Microorganisms for therapy | |
| GB2399017B (en) | Aortic catheter | |
| GB0415181D0 (en) | Compounds for use in the treatment of infection | |
| EP1525852A4 (en) | CATHETER | |
| GB0321120D0 (en) | Catheters | |
| SI1535612T1 (sl) | Zdravljenje hiperurikemije | |
| GB0403352D0 (en) | Bath 'n' easy | |
| AU2003253284A1 (en) | A catheter for cerebral treatment with radioactive substances | |
| GB0300547D0 (en) | Medical poultices | |
| GB0301792D0 (en) | Medical bandage | |
| GB0218734D0 (en) | Catheter | |
| GB0412341D0 (en) | Thiazole compounds in medicine | |
| PL114875U1 (en) | Shelving for the handicapped persons | |
| AU155212S (en) | Wheelchair | |
| GB0312722D0 (en) | Wheelchair | |
| GB0406070D0 (en) | Liquid effluent treatment |